The in vitro activity of FK-037, 5-amino-2-[[(6R, 7R)-7-[[(Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino) acetyl] aminol-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yllmethyl1-1-(2-hydroxyethyl)-lH-pyrazolium hydroxide, inner salt, sulfate (1:1), a new parenteral cephem, was compared with those of cefepime, ceftazidime, imipenem, and ciprofloxacin. FK-037 inhibited methicillin-susceptible staphylococci at c4 jig/ml. Of 98 isolates of homogenous methicillin-resistant Staphylococcus aureus, 55 (56.1%) were inhibited by 8 jig of FK-037 per ml, compared to 3.1% for cefepime. Imipenem was the most active 13-lactam tested against staphylococci. The MIC of FK-037 for 90o of the strains tested (MIC90) was 0.06 ,ug/ml for hemolytic streptococci, Streptococcus pneumoniae, viridans group streptococci, and Streptococcus bovis. The MIC90 for many of the members of the family Enterobacteriaceae was 1 ji.g/ml, similar to that of cefepime and lower than those of ceftazidime and imipenem. The MIC,0 for KiebsieUla pneumonwiae and Enterobacter cloacae was 8 jug/ml, similar to that for cefepime, but all isolates were inhibited by 2 ,ig of imipenem per ml. K. pneumoniae isolates with cefotaxime and ceftazidime MICs of >32 jig/ml with Bush type 2b' 13-lactamases were inhibited by 4 jig of FK-037 per ml. E. cloacae, Citrobacterfreundii, and S. aureus stably resistant to FK-037 could be selected by repeated transfer in the presence of FK-037. The FK-037 MIC90 for Pseudomonas aeruginosa was 4 ,Ig/ml, compared to 32 jug/ml for cefepime and ceftazidime and 8 pg/ml for imipenem. Xanthomonas maltophilia, Pseudomonas cepacia, Acinetobacter anitratus, and Bacteroides species were resistant to FK-037 (MIC, >32 ,ig/ml). MBCs were identical to or within twofold of the MICs except for a 32-fold greater MBC for P. aeruginosa. Inoculum size and acid environment did not lower the activity of FK-037. FK-037 was not appreciably hydrolyzed by Bush group 1, 2a, 2b, and 2e 1-lactamases but was hydrolyzed by 2b' and 2d enzymes at rates comparable to that of ceftazidime. Nonetheless, FK-037 inhibited bacteria possessing TEM-3, -5, and -7 and SHV-5 at <8 ,ug/ml. Overall, FK-037 has lower MICs against staphylococci and P. aeruginosa than the currently available iminomethoxy aminothiazolyl cephalosporins and has activity against members of the family Enterobacteriaceae comparable to that of cefepime.
Although a number of parenteral cephalosporins have been synthesized during the past 2 decades, there has been continued interest in finding new cephalosporins with improved activity against gram-positive bacteria, particularly for methicillin-resistant staphylococci, and which retain the excellent activity of the aminothiazolyl cephalosporins against gram-negative organisms. FK-037, an oxime-type cephem, contains a 1-hydroxyethyl-5-amino pyra-zoliomethyl moiety at position 3 of the cephem ring. Preliminary studies showed FK-037 to have a broad spectrum of antibacterial activity against gram-negative and gram-positive bacteria, including methicillin-resistant staphylococci (2, 3) . We compared the in vitro activity of FK-037 with those of cefepime, ceftazidime, imipenem, and ciprofloxacin against clinical isolates and determined its stability and the affinity of ,3-lactamases for FK-037.
MATERIALS AND METHODS
Bacterial strains. The organisms were isolated from patients admitted to the Columbia-Presbyterian Medical Center in New York City during the past 2 years. Staphylococci were collected from blood isolates within the last 2 years. S. recorded, and the terminal MICs were compared with the initial MICs. To assess whether resistance was a stable mutation or an inducible event, we subcultured the resistant organisms daily in an antibiotic-free broth 10 successive times.
IN VITRO ACTIVITY AND P-LACTAMASE STABILITY OF FK-037
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,-Lactamase stability was determined by a spectrophotometric assay by using the change in maximum absorption (6) . Cephaloridine was used as a reference compound. Inhibition of hydrolysis of cephaloridine was performed by preincubation of the enzymes with the inhibitors for 10 min prior to adding cephaloridine to the reaction mixture. Enzymes were purified by column separation as described previously (6) . The classification of 13-lactamases was that of Bush (1) .
RESULTS
The in vitro activities of FK-037 and the other agents tested against gram-negative organisms are shown in Table   1 . FK-037 inhibited 50% of the members of the family Enterobacteriaceae at .0.12 ,ug/ml, and the MIC for 90% of the strains tested (MIC90) was c1 ,ug/ml, except for E.
cloacae and Providencia rettgeri, for which the FK-037 MIC90 was 8 ,ug/ml. In comparison with cefepime, ceftazidime, and imipenem, FK-037 was equal to or 2-to 8-fold more active than cefepime and 4-to 16-fold more active than ceftazidime and imipenem against E. coli, Klebsiella pneumoniae, Enterobacter aerogenes, C. freundii, and Serratia, Providencia, Salmonella, and Shigella species. Cefepime was twofold more active than FK-037 against Morganella spp. and Proteus mirabilis. Ciprofloxacin at <2 ,ug/ml inhibited isolates which were resistant to the P-lactams. K. pneumoniae isolates resistant to cefotaxime and ceftazidime were susceptible to FK-037 and cefepime, with MIC90s of 4 and 1 ,tg/ml, respectively. E. cloacae was more susceptible to cefepime, imipenem, and ciprofloxacin. Ninety percent of Pseudomonas aeruginosa isolates were inhibited at 4 ,ug of FK-037 per ml compared to MIC90s of 32 ,ug/ml for cefepime and ceftazidime and 8 ,ug/ml for imipenem. Some isolates resistant to imipenem and ciprofloxacin were inhibited by FK-037. Ninety percent of Haemophilus influenzae and Neisseria gonorrhoeae isolates were inhibited by 0.06 ,ug of FK-037 per ml. The FK-037 MIC9E was 2 ,g/ml for Moraxella catarrhalis. Fifty percent of Pseudomonas cepacia and Acinetobacter anitratus isolates were inhibited by 4 ,ug/ml, but the FK-037 MICs for Xanthomonas maltophilia were .64 ,ug/ml. FK-037 inhibited most gram-positive organisms (Table 2) . Two hundred eighty-eight isolates of staphylococci were tested. FK-037 at .16 ,ug/ml inhibited 50% of the S. aureus isolates for which the oxacillin MICs were .16 ,ug/ml. The S. aureus isolates for which the oxacillin MICs were 8 ,ug/ml were inhibited by c4 ,g/ml compared to .32 ,ug/ml for cefepime. FK-037 inhibited 90% of methicillin-susceptible S. aureus isolates at .2 ,ug/ml. FK-037 at 8 ,ug/ml inhibited 50% of the Staphylococcus epidermidis isolates for which the oxacillin MICs were .16 ,ug/ml. The FK-037 MIC90s were <0.06 ,ug/ml for beta-hemolytic streptococci, Streptococcus pneumoniae, viridans group streptococci, and Streptococcus bovis. The activity of FK-037 against these species was similar to that of cefepime and two-to fourfold less than imipenem and ceftazidime. Enterococci, Listeria spp., and most anaerobic species were resistant to FK-037, cefepime, and ceftazidime but not to imipenem. follows: E. coli, 0.06 and 0.06 ,g/ml; K pneumoniae, 0.09 and 0.07 ,g/ml; C. freundii, 1.72 and 0.08 jig/ml; E. cloacae, 0.31 and 0.45 ,ug/ml; P. aenrginosa, 4.6 and 2 p,g/ml; and S. aureus, 0.19 and 1.14 p,g/ml.
The FK-037 MBCs were identical to or within one dilution of the MICs for E. coli and S. aureus, but MBCs were 32-fold greater than the MICs for P. aeruginosa (Table  3) .
FK-037 was not hydrolyzed (relative rate, <0.1%) compared with cephaloridine by TEM-1, TEM-2, SHV-1, K-1, PC-1, P-99, Morganella morganii, Proteus vulgaris, and M. catarrhalis (Bro 1) ( Table 4 ). This was in general similar to what we found for cefotaxime and ceftazidime with similar amounts of these purified enzymes. Cefotaxime was hydrolyzed by the P. vulgaris ,-lactamase. FK-037 had a relative rate of hydrolysis by TEM-3, TEM-7, and TEM-9 comparable to the relative rates of hydrolysis of cefotaxime and ceftazidime. FK-037 was not tested at low concentrations with group 1 enzymes. We compared the affinities of the E. cloacae P99 ,-lactamase for FK-037, cefepime, cefotaxime, and ceftazidime at a single concentration of 50 mM. Cefotaxime caused 99% inhibition of the hydrolysis of cephaloridine, 89% inhibition of the hydrolysis of ceftazidime, and 21% inhibition of the hydrolysis of FK-037 and cefepime.
The MICs for isolates containing characterized 3-lactamases are shown in Table 5 . FK-037 inhibited those isolates at <8 ,ug/ml, with the exception of a strain of C. freundii containing TEM-9 (MIC, 32 ,g/ml). In general, FK-037 had activity against these isolates similar to those of cefepime and cefpirome. The activity of FK-037 against two permeability mutants of E. coli was determined. The FK-037 MIC for the parent strain, UB-1005, was 0.03 ,ug/ml, and that for mutants DC-1 and DC-3 was 0.015 ,ug/ml. For the same isolates, the MICs of cefepime and cefpirome were 0.06 and 0.03 ,ug/ml for UB-1005 and 0.015 ,g/ml for DC-1 and DC-3.
This indicates that there is a minimal barrier to entry of FK-037 similar to those for cefepime and cefpirome.
The development of progressive resistance was determined for two isolates each of E. cloacae, C. freundii, and S. aureus. The FK-037 MICs for the S. aureus isolates rose from 2 to 4 ,ug/ml and 2 to 8 ,ug/ml after 14 days. The MICs did not decrease after repeated subculture. The MICs for E.
cloacae rose from 0.25 to 1 ,g/ml to >64 ,ug/ml. The MICs ,ug/ml, respectively. These elevated MICs remained after 10 subcultures in the absence of drug.
DISCUSSION
Although the commercially available cephalosporins in this study inhibit many of the members of the family Enterobacteriaceae and streptococci at readily achievable concentrations clinically, their activity against some cephalosporinase-producing organisms is less, and they do not inhibit methicillin-resistant staphylococci. As pointed out by Sanders (8) (9) .
The inoculum size effect and discrepancy of the MBC/ MIC ratio for P. aeruginosa suggests that resistance will develop, and it is possible to select stably resistant isolates of E. cloacae and C. freundii.
FK-037 was the most active cephalosporin tested against some methicillin-resistant staphylococci, but whether this will be of clinical importance could only be seen by clinical trials. FK-037 was not hydrolyzed by many ,-lactamases. Cefpirome, not tested in this study, also inhibits methicillinsusceptible S. aureus at similar concentrations. Cefpirome contains a quaternary ammonium moiety at C-3. The characteristics of FK-037 could provide protection from destruction in vivo. Further animal studies and pharmacological studies with humans are necessary to assess whether this agent can be successfully developed for clinical use. 
